|
Synonyms: IPH-4102 | IPH4102
Compound class:
Antibody
Comment: Lacutamab (IPH4102) is a humanized anti-KIR3DL2, cytotoxicity-inducing, monoclonal antibody [3-4,6].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use ![]() |
| Lacutamab (IPH4102) was progressed as a clinical candidate, principally as a treatment for cutaneous T-cell lymphomas (CTCL) that commonly expresse KIR3DL2 [2,4,6]. IPH4102 was granted orphan drug status in the European Union and in the United States for the treatment of CTCL, and in January 2019 received FDA fast track designation for Sézary syndrome, to expedite its development and regulatory review in this patient subset (based on preliminary Phase I results that demonstrated significant clinical activity [5]). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05321147 | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 | Phase 1 Interventional | Innate Pharma | ||
| NCT03902184 | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma | Phase 2 Interventional | Innate Pharma | ||
| NCT02593045 | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) | Phase 1 Interventional | Innate Pharma | 1 | |